FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.39
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$34.77

22 Jan
2025

0.080

OPEN

$35.25

0.23%

HIGH

$35.25

356,983

LOW

$34.41

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 55.6 xxx
DPS (cps) 42.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 63.3 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 77.1% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.35%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.06

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/12 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx21.1
DPS All xxxxxxxxxxxxxxx45.3
Sales/Revenue xxxxxxxxxxxxxxx1,629.7 M
Book Value Per Share xxxxxxxxxxxxxxx276.4
Net Operating Cash Flow xxxxxxxxxxxxxxx398.2 M
Net Profit Margin xxxxxxxxxxxxxxx7.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.56 %
Return on Invested Capital xxxxxxxxxxxxxxx7.12 %
Return on Assets xxxxxxxxxxxxxxx5.92 %
Return on Equity xxxxxxxxxxxxxxx7.56 %
Return on Total Capital xxxxxxxxxxxxxxx19.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx88 M
Long Term Debt xxxxxxxxxxxxxxx85 M
Total Debt xxxxxxxxxxxxxxx173 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx75 M
Price To Book Value xxxxxxxxxxxxxxx8.51

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx314.2 M
Capex % of Sales xxxxxxxxxxxxxxx19.28 %
Cost of Goods Sold xxxxxxxxxxxxxxx647 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx641 M
Research & Development xxxxxxxxxxxxxxx184 M
Investments - Total xxxxxxxxxxxxxxx49 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

29/11/2024

5

Sell

-

-

Fisher & Paykel Healthcare reported 1H25 revenue and earnings slightly above consensus estimates, Citi notes. Reported net profit after tax was -3% below consensus due to FX impacts.

The broker identifies a boost from flu activity and higher post-COVID hospitalisations as drivers for 1H25 results.

Management retained FY25 guidance, including expectations for a more "moderate" flu season, which may limit earnings upgrades.

Citi reduces EPS forecasts by -2.2% and -0.9% for FY25 and FY26, respectively.

No change to the Sell rating with a NZ$33.50 target price.

FORECAST
Citi forecasts a full year FY25 dividend of 40.27 cents and EPS of 54.63 cents.
Citi forecasts a full year FY26 dividend of 49.24 cents and EPS of 66.53 cents.

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

4

xxxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

02/12/2024

3

Downgrade to Market Weight from Overweight

$34.93

0.46%

Wilsons notes Fisher & Paykel Healthcare's first-half results included 19% revenue growth year-on-year, with solid performance in Hospital and Homecare segments.

Gross margin reached 61.9%, exceeding guidance, though the broker anticipates softer improvement ahead with potential headwinds in FY26.

NewApps consumables grew 27%, driven by adoption in new settings such as anaesthesia, while Homecare benefited from mask launches and durable resupply demand, explains the analyst.

Wilsons lowers profit  forecasts by between -2% to -4% for FY25-FY27, reflecting expectations for slower gross margin development. The rating is downgraded to Market Weight from Overweight, and the target eases to $34.93 from $35.

FORECAST
Wilsons forecasts a full year FY25 dividend of 38.89 cents and EPS of 52.99 cents.
Wilsons forecasts a full year FY26 dividend of 43.93 cents and EPS of 63.60 cents.
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
2
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
3
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
4
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
5
FNArena Corporate Results Monitor – 09-12-2024

Dec 09 2024 - Australia

Latest Medical Equipment & Devices News

1
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
2
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
3
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
4
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
5
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
6
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
7
ResMed Silences The Doubters

Apr 29 2024 - Australia
8
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
9
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
10
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia